keyword
MENU ▼
Read by QxMD icon Read
search

Keynote

keyword
https://www.readbyqxmd.com/read/28884644/the-role-of-language-in-expressing-the-life-sciences-in-a-polarized-age
#1
Kathleen Hall Jamieson
This Perspective is based on the keynote plenary lecture delivered at the Annual Conference of the Association for Politics and the Life Sciences (APLS), held on October 23, 2015, at the University of Wisconsin-Madison.
2017: Politics and the Life Sciences: the Journal of the Association for Politics and the Life Sciences
https://www.readbyqxmd.com/read/28880735/2017-midwest-zebrafish-meeting-report
#2
Elizabeth Sandquist, Sarah C Petersen, Cody J Smith
The 2017 Midwest Zebrafish meeting was held from June 16 to 18 at the University of Cincinnati, sponsored by the Cincinnati Children's Hospital Divisions of Developmental Biology, Molecular Cardiovascular Biology, and Gastroenterology, Hepatology, and Nutrition. The meeting, organized by Saulius Sumanas, Joshua Waxman, and Chunyue Yin, hosted >130 attendees from 16 different states. Scientific sessions were focused on morphogenesis, neural development, novel technologies, and disease models, with Steve Ekker, Stephen Potter, and Lila Solnica-Krezel presenting keynote talks...
September 7, 2017: Zebrafish
https://www.readbyqxmd.com/read/28837405/safety-and-antitumor-activity-of-pembrolizumab-in-patients-with-programmed-death-ligand-1-positive-nasopharyngeal-carcinoma-results-of-the-keynote-028-study
#3
Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B Cohen, Christophe Le Tourneau, Janice M Mehnert, Alain Algazi, Emilie M J van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D Cheng, Aaron R Hansen
Purpose To establish the safety profile and antitumor activity of the anti-programmed death 1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) that expressed programmed death-ligand 1 (PD-L1). Patients and Methods KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors. Key eligibility criteria for the NPC cohort included unresectable or metastatic disease, failure on prior standard therapy, and PD-L1 expression in 1% or more of tumor cells or tumor-infiltrating lymphocytes...
August 24, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28835513/fda-approval-summary-pembrolizumab-for-treatment-of-metastatic-non-small-cell-lung-cancer-first-line-therapy-and-beyond
#4
Lee Pai-Scherf, Gideon M Blumenthal, Hongshan Li, Sriram Subramaniam, Pallavi S Mishra-Kalyani, Kun He, Hong Zhao, Jingyu Yu, Mark Paciga, Kirsten B Goldberg, Amy E McKee, Patricia Keegan, Richard Pazdur
On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] ≥50%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS ≥1%), with disease progression on or after platinum-containing chemotherapy...
August 23, 2017: Oncologist
https://www.readbyqxmd.com/read/28822577/keynote-006-a-success-in-melanoma-but-a-long-way-to-go
#5
Kilian Wistuba-Hamprecht, Graham Pawelec
No abstract text is available yet for this article.
August 16, 2017: Lancet
https://www.readbyqxmd.com/read/28822576/pembrolizumab-versus-ipilimumab-for-advanced-melanoma-final-overall-survival-results-of-a-multicentre-randomised-open-label-phase-3-study-keynote-006
#6
Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian Blank, Teresa M Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert
BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis. METHODS: In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia, Austria, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norway, Spain, Sweden, UK, and USA)...
August 16, 2017: Lancet
https://www.readbyqxmd.com/read/28813164/pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer-results-from-the-phase-ib-keynote-028-study
#7
Patrick A Ott, Elena Elez, Sandrine Hiret, Dong-Wan Kim, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Janice M Mehnert
Purpose The safety and efficacy of pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), were assessed in patients with programmed death ligand 1 (PD-L1)-expressing extensive-stage small-cell lung cancer (SCLC) in the multicohort, phase Ib open-label KEYNOTE-028 study ( ClinicalTrials.gov identifier: NCT02054806). Methods Patients with SCLC received pembrolizumab 10 mg/kg every 2 weeks for 24 months or until disease progression or intolerable toxicity occurred. PD-L1 expression was assessed by immunohistochemistry...
August 16, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28811837/an-interview-with-samuel-shem-author-of-the-house-of-god
#8
Claire Brash
Dr Stephen Bergman, Professor of medical humanities at New York University, writes under the name Samuel Shem. He is an acclaimed author of several novels, plays and textbooks, and his work has been translated into several languages -'The House of God' his first novel has sold over 3 million copies. His work exposes the potential moral challenges of the medical workplace and the connection between values, good relationships and healing. In 2015 he visited the UK for medical humanities academic tour which included keynote talks at the RCGP 2015 Annual Conference and at the Royal Society of Medicine...
July 2017: London Journal of Primary Care
https://www.readbyqxmd.com/read/28774800/highlights-of-the-30th-international-conference-on-antiviral-research
#9
Graciela Andrei, Kara Carter, Zlatko Janeba, Aruna Sampath, Luis M Schang, E Bart Tarbet, R Anthony Vere Hodge, Mike Bray, José A Esté
The 30th International Conference on Antiviral Research (ICAR) was held in Atlanta, GA, USA from May 18 to 21, 2017. This report provides an account of award lectures, invited keynote addresses and oral presentations during the meeting. The 2017 Gertrude Elion Memorial Lecture Award by Michael Sofia highlighted one of the most important accomplishments in recent drug discovery in antiviral research, the identification of the hepatitis C virus direct-acting antiviral sofosbuvir and new alternatives to combat hepatitis B virus (HBV) infection...
August 1, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28766200/keynote-address-at-the-american-society-of-breast-surgeons-18th-annual-meeting-current-and-future-application-of-intraoperative-radiotherapy-iort-in-the-curative-and-palliative-treatment-of-breast-cancer
#10
Frederik Wenz
Intraoperative radiotherapy (IORT) is increasingly used worldwide. Breast cancer is the most rapidly growing indication for IORT, approaching 70-80% of cases in most centers. This report reviews the theoretical background and clinical use of IORT for primary and metastasized breast cancer. There are established applications such as tumor bed boost during breast-conserving surgery followed by whole breast radiotherapy or IORT as a form of accelerated partial-breast irradiation (APBI) for selected patients. Novel applications such as IORT for vertebral or brain metastases are presented as well as technological developments, widening the spectrum of potential clinical applications for IORT...
August 1, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28762840/prevention-in-the-elderly-a-necessary-priority-for-general-practitioners
#11
Christos Lionis, Patrik Midlöv
Prevention is viewed as a key issue for general practice, yet there is a lack of evidence regarding general practitioners' interventions in both middle-aged and elderly people. This is despite the fact that recommendations and key indicators for monitoring the use of clinical preventive strategies aimed at these groups are available and that both the World Health Organization and European Commission endorse the importance of interventions for healthy and active ageing. This paper draws on two keynote presentations given at the 2015 autumn meeting of the European General Practice Research Network (EGPRN) in Edirne, Turkey (17-20 October 2015)...
December 2017: European Journal of General Practice
https://www.readbyqxmd.com/read/28760910/epacadostat-shows-value-in-two-scchn-trials
#12
(no author information available yet)
In the ECHO-202/KEYNOTE-037 and ECHO-204 trials reported at the 2017 Annual Meeting of the American Society of Clinical Oncology, patients with squamous cell carcinoma of the head and neck responded well to the combinations of epacadostat plus pembrolizumab and epacadostat plus nivolumab. An IDO1 inhibitor, epacadostat also demonstrated promising activity in combination with the PD-1 checkpoint inhibitors in other solid tumors, including melanoma, urothelial carcinoma, renal cell carcinoma, and non-small cell lung cancer...
July 31, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28737012/diabetes-news
#13
Ann M Carracher, Payal H Marathe, Kelly L Close
More than 550 people gathered in Keystone, Colorado, USA for the 27th annual Practical Ways to Achieve Targets in Diabetes Care (ATDC) Conference. In a keynote lecture on the best of the American Diabetes Association's (ADA) 2017 Scientific Sessions, the organization's Chief Scientific, Medical, and Mission Officer Dr. William Cefalu summarized new data in the diabetes field.
July 24, 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/28735481/single-cell-mass-cytometry-of-acute-myeloid-leukemia-and-leukemia-stem-progenitor-cells
#14
Zhihong Zeng, Marina Konopleva, Michael Andreeff
Mass cytometry time-of-flight (CyTOF) empowers us to understand acute myeloid leukemia (AML) biology at the single-cell level. This technology, combined with advanced data-analysis methods, enables identification and characterization of the rare AML stem/progenitor cells that play key roles in drug resistance and AML relapse. Here we provide a protocol for AML sample preparation for CyTOF and keynotes emphasizing critical steps in and troubleshooting strategies for this procedure.
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28734287/on-the-thermophysical-and-transport-properties-of-3-he-and-4-he-a-bubble-interaction-potential-versus-state-of-the-art
#15
Michael Chrysos, Henri Piel
Three keynote thermophysical and transport properties of (3)He and (4)He, namely, the second virial coefficient, the shear viscosity, and the thermal conductivity, are reported for the "extended Dirac bubble potential" (EDbp), a novel model for He-He [M. Chrysos, J. Chem. Phys. 146, 024106 (2017)]. Comparisons with the experiment as well as with potentials with a proven track record and with the oversimplified Dbp are being made in the range 0.1-500 K to analyze the performance of the EDbp, which is shown here to emerge as a promising analytic model for He-He...
July 21, 2017: Journal of Chemical Physics
https://www.readbyqxmd.com/read/28729151/standard-dose-pembrolizumab-in-combination-with-reduced-dose-ipilimumab-for-patients-with-advanced-melanoma-keynote-029-an-open-label-phase-1b-trial
#16
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson, Bernie M Fitzharris, Catriona M McNeil, Andrew G Hill, Antoni Ribas, Michael B Atkins, John A Thompson, Wen-Jen Hwu, F Stephen Hodi, Alexander M Menzies, Alexander D Guminski, Richard Kefford, Benjamin Y Kong, Babak Tamjid, Archana Srivastava, Anna J Lomax, Mohammed Islam, Xinxin Shu, Scot Ebbinghaus, Nageatte Ibrahim, Matteo S Carlino
BACKGROUND: Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combination with reduced-dose ipilimumab. METHODS: In this open-label, phase 1b trial, we recruited patients from 12 medical centres in Australia, New Zealand, and the USA. Eligible patients were aged at least 18 years, had advanced melanoma, had an Eastern Coooperative Oncology Group performance status of 0 or 1, had measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1...
September 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28721314/medical-school-hotline-john-a-burns-school-of-medicine-university-of-hawai-i-at-manoa-convocation-ceremony-keynote-address-may-14-2017
#17
Raquel C Bono
No abstract text is available yet for this article.
July 2017: Hawai'i Journal of Medicine & Public Health: a Journal of Asia Pacific Medicine & Public Health
https://www.readbyqxmd.com/read/28719313/keynote-address-november-2016-zika-virus-disease-in-the-americas-a-storm-in-the-making
#18
Carissa Etienne, Thais Dos Santos, Marcos A Espinal
More than 700,000 cases of Zika virus (ZIKAV) disease have been officially reported to the Pan American Health Organization (PAHO) from 48 countries and territories of the Americas. The response led by the PAHO and partners suggests major lessons of this outbreak. A seemingly innocuous pathogen became the new villain, causing fear, economic losses and, most importantly, debilitating birth defects and neurological problems, reaffirming the well-known war principle of never to underestimate one's opponent. The ZIKAV tested public health capacities under the International Health Regulations, highlighting the need for continued investment in health security...
July 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28713548/2017-iscb-accomplishment-by-a-senior-scientist-award-pavel-pevzner
#19
EDITORIAL
Christiana N Fogg, Diane E Kovats, Bonnie Berger
The International Society for Computational Biology ( ISCB) recognizes an established scientist each year with the Accomplishment by a Senior Scientist Award for significant contributions he or she has made to the field. This award honors scientists who have contributed to the advancement of computational biology and bioinformatics through their research, service, and education work. Pavel Pevzner, PhD, Ronald R. Taylor Professor of Computer Science and Director of the NIH Center for Computational Mass Spectrometry at University of California, San Diego, has been selected as the winner of the 2017 Accomplishment by a Senior Scientist Award...
2017: F1000Research
https://www.readbyqxmd.com/read/28713547/2017-iscb-innovator-award-aviv-regev
#20
EDITORIAL
Christiana N Fogg, Diane Kovats, Bonnie Berger
2017 marks the second year of the International Society for Computational Biology (ISCB) Innovator Award, which recognizes an ISCB scientist who is within two decades of having completed his or her graduate degree and has consistently made outstanding contributions to the field. The 2017 winner is Dr. Aviv Regev, Professor of Biology at the Massachusetts Institute of Technology (MIT), a Core Member and Chair of the Faculty of the Broad Institute of MIT and Harvard, and an HHMI Investigator. Regev will receive her award and deliver a keynote address during International Conference on Intelligent Systems for Molecular Biology/European Conference on Computational Biology (ISMB/ECCB) 2017 in Prague, Czech Republic (July 21 - 25, 2017)...
2017: F1000Research
keyword
keyword
56519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"